array(40) {
  [0]=>
  string(5) "10469"
  ["article_id"]=>
  string(5) "10469"
  [1]=>
  string(74) "First Mining Files Early Warning Report in Respect of Treasury Metals Inc."
  ["article_title"]=>
  string(74) "First Mining Files Early Warning Report in Respect of Treasury Metals Inc."
  [2]=>
  string(166) "VANCOUVER, BC, July 15, 2021 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) announ"
  ["short_description"]=>
  string(166) "VANCOUVER, BC, July 15, 2021 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) announ"
  [3]=>
  string(320) "
VANCOUVER, BC, July 15, 2021 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) announces that it has filed an early warning report with respect to Treasury Metals Inc. (the "Treasury Metals") in connection with First'...
"
  ["description"]=>
  string(320) "
VANCOUVER, BC, July 15, 2021 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) announces that it has filed an early warning report with respect to Treasury Metals Inc. (the "Treasury Metals") in connection with First'...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(133) "https://www.prnewswire.com:443/news-releases/first-mining-files-early-warning-report-in-respect-of-treasury-metals-inc-301335372.html"
  ["blog_url"]=>
  string(133) "https://www.prnewswire.com:443/news-releases/first-mining-files-early-warning-report-in-respect-of-treasury-metals-inc-301335372.html"
  [15]=>
  string(19) "2021-07-16 10:41:00"
  ["add_date"]=>
  string(19) "2021-07-16 10:41:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:14"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10440"
  ["article_id"]=>
  string(5) "10440"
  [1]=>
  string(59) "Erasca Announces Pricing of Upsized Initial Public Offering"
  ["article_title"]=>
  string(59) "Erasca Announces Pricing of Upsized Initial Public Offering"
  [2]=>
  string(150) "SAN DIEGO, July  15, 2021  (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discover"
  ["short_description"]=>
  string(150) "SAN DIEGO, July  15, 2021  (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discover"
  [3]=>
  string(1156) "
SAN DIEGO, July  15, 2021  (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its upsized initial public offering of 18,750,000 shares of common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Erasca. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, are expected to be $300.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on July 16, 2021 under the ticker symbol “ERAS.” The offering is expected to close on July 20, 2021, subject to the satisfaction of customary closing conditions. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
"
  ["description"]=>
  string(1156) "
SAN DIEGO, July  15, 2021  (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its upsized initial public offering of 18,750,000 shares of common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Erasca. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, are expected to be $300.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on July 16, 2021 under the ticker symbol “ERAS.” The offering is expected to close on July 20, 2021, subject to the satisfaction of customary closing conditions. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(131) "https://www.globenewswire.com/news-release/2021/07/16/2264065/0/en/Erasca-Announces-Pricing-of-Upsized-Initial-Public-Offering.html"
  ["blog_url"]=>
  string(131) "https://www.globenewswire.com/news-release/2021/07/16/2264065/0/en/Erasca-Announces-Pricing-of-Upsized-Initial-Public-Offering.html"
  [15]=>
  string(19) "2021-07-16 09:58:00"
  ["add_date"]=>
  string(19) "2021-07-16 09:58:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10470"
  ["article_id"]=>
  string(5) "10470"
  [1]=>
  string(90) "Pew Urges WTO Members to Prioritize Fisheries Subsidies Effort After Deal Is Delayed Again"
  ["article_title"]=>
  string(90) "Pew Urges WTO Members to Prioritize Fisheries Subsidies Effort After Deal Is Delayed Again"
  [2]=>
  string(150) "Agreement could boost fish populations, improve ocean health, and help coastal communities GENEVA, July 16, 2021 /PRNewswire/ -- The Pew Charitable Tr"
  ["short_description"]=>
  string(150) "Agreement could boost fish populations, improve ocean health, and help coastal communities GENEVA, July 16, 2021 /PRNewswire/ -- The Pew Charitable Tr"
  [3]=>
  string(294) "
Agreement could boost fish populations, improve ocean health, and help coastal communities GENEVA, July 16, 2021 /PRNewswire/ -- The Pew Charitable Trusts expressed cautious optimism today that World Trade Organization members could soon reach an agreement to reduce harmful fisheries...
"
  ["description"]=>
  string(294) "
Agreement could boost fish populations, improve ocean health, and help coastal communities GENEVA, July 16, 2021 /PRNewswire/ -- The Pew Charitable Trusts expressed cautious optimism today that World Trade Organization members could soon reach an agreement to reduce harmful fisheries...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(150) "https://www.prnewswire.com:443/news-releases/pew-urges-wto-members-to-prioritize-fisheries-subsidies-effort-after-deal-is-delayed-again-848244536.html"
  ["blog_url"]=>
  string(150) "https://www.prnewswire.com:443/news-releases/pew-urges-wto-members-to-prioritize-fisheries-subsidies-effort-after-deal-is-delayed-again-848244536.html"
  [15]=>
  string(19) "2021-07-16 09:01:00"
  ["add_date"]=>
  string(19) "2021-07-16 09:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:14"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10441"
  ["article_id"]=>
  string(5) "10441"
  [1]=>
  string(102) "Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference"
  ["article_title"]=>
  string(102) "Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference"
  [2]=>
  string(150) "NEW YORK, July  15, 2021  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammator"
  ["short_description"]=>
  string(150) "NEW YORK, July  15, 2021  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammator"
  [3]=>
  string(741) "
NEW YORK, July  15, 2021  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). Results of respiratory function were highlighted at the biennial Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases conference hosted by the University of Vermont, Burlington, VT, on July 15. The invited presentation was given by Mesoblast Chief Executive Officer, Dr Silviu Itescu, and materials have been lodged with the ASX.
"
  ["description"]=>
  string(741) "
NEW YORK, July  15, 2021  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). Results of respiratory function were highlighted at the biennial Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases conference hosted by the University of Vermont, Burlington, VT, on July 15. The invited presentation was given by Mesoblast Chief Executive Officer, Dr Silviu Itescu, and materials have been lodged with the ASX.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(174) "https://www.globenewswire.com/news-release/2021/07/16/2264054/0/en/Mesoblast-Presents-Respiratory-Function-Results-of-COVID-19-ARDS-Trial-at-Pulmonary-Disease-Conference.html"
  ["blog_url"]=>
  string(174) "https://www.globenewswire.com/news-release/2021/07/16/2264054/0/en/Mesoblast-Presents-Respiratory-Function-Results-of-COVID-19-ARDS-Trial-at-Pulmonary-Disease-Conference.html"
  [15]=>
  string(19) "2021-07-16 08:15:00"
  ["add_date"]=>
  string(19) "2021-07-16 08:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10442"
  ["article_id"]=>
  string(5) "10442"
  [1]=>
  string(83) "Industry Leader, iCRYO Adds Two Add Elite Services to Enhance Their Franchise Model"
  ["article_title"]=>
  string(83) "Industry Leader, iCRYO Adds Two Add Elite Services to Enhance Their Franchise Model"
  [2]=>
  string(150) "iCRYO adds Zerobody Dry Floatation and Photobiomodulation (PBM Therapy) to their list of health and wellness services. iCRYO adds Zerobody Dry Floatat"
  ["short_description"]=>
  string(150) "iCRYO adds Zerobody Dry Floatation and Photobiomodulation (PBM Therapy) to their list of health and wellness services. iCRYO adds Zerobody Dry Floatat"
  [3]=>
  string(248) "iCRYO adds Zerobody Dry Floatation and Photobiomodulation (PBM Therapy) to their list of health and wellness services. 
iCRYO adds Zerobody Dry Floatation and Photobiomodulation (PBM Therapy) to their list of health and wellness services.
"
  ["description"]=>
  string(248) "iCRYO adds Zerobody Dry Floatation and Photobiomodulation (PBM Therapy) to their list of health and wellness services. 
iCRYO adds Zerobody Dry Floatation and Photobiomodulation (PBM Therapy) to their list of health and wellness services.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(154) "https://www.globenewswire.com/news-release/2021/07/15/2264036/0/en/Industry-Leader-iCRYO-Adds-Two-Add-Elite-Services-to-Enhance-Their-Franchise-Model.html"
  ["blog_url"]=>
  string(154) "https://www.globenewswire.com/news-release/2021/07/15/2264036/0/en/Industry-Leader-iCRYO-Adds-Two-Add-Elite-Services-to-Enhance-Their-Franchise-Model.html"
  [15]=>
  string(19) "2021-07-16 07:30:00"
  ["add_date"]=>
  string(19) "2021-07-16 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10443"
  ["article_id"]=>
  string(5) "10443"
  [1]=>
  string(123) "FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease"
  ["article_title"]=>
  string(123) "FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease"
  [2]=>
  string(150) "SAN FRANCISCO, July  15, 2021  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Card"
  ["short_description"]=>
  string(150) "SAN FRANCISCO, July  15, 2021  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Card"
  [3]=>
  string(691) "
SAN FRANCISCO, July  15, 2021  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. The Committee based its recommendation on data from a global Phase 3 program encompassing more than 8,000 patients. While the FDA is not required to follow the Committee's vote, the agency considers the Committee's non-binding recommendations when making its decision.
"
  ["description"]=>
  string(691) "
SAN FRANCISCO, July  15, 2021  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. The Committee based its recommendation on data from a global Phase 3 program encompassing more than 8,000 patients. While the FDA is not required to follow the Committee's vote, the agency considers the Committee's non-binding recommendations when making its decision.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(199) "https://www.globenewswire.com/news-release/2021/07/15/2264019/33525/en/FibroGen-Announces-Outcome-of-FDA-Advisory-Committee-Review-of-Roxadustat-for-Treatment-of-Anemia-of-Chronic-Kidney-Disease.html"
  ["blog_url"]=>
  string(199) "https://www.globenewswire.com/news-release/2021/07/15/2264019/33525/en/FibroGen-Announces-Outcome-of-FDA-Advisory-Committee-Review-of-Roxadustat-for-Treatment-of-Anemia-of-Chronic-Kidney-Disease.html"
  [15]=>
  string(19) "2021-07-16 06:26:00"
  ["add_date"]=>
  string(19) "2021-07-16 06:26:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10309"
  ["article_id"]=>
  string(5) "10309"
  [1]=>
  string(66) "Two Major Health Systems Will Not Administer Controversial Aduhelm"
  ["article_title"]=>
  string(66) "Two Major Health Systems Will Not Administer Controversial Aduhelm"
  [2]=>
  string(150) "THURSDAY, July 15, 2021 -- Two major U.S. health systems say they will not administer Aduhelm, the controversial new drug for treating Alzheimer disea"
  ["short_description"]=>
  string(150) "THURSDAY, July 15, 2021 -- Two major U.S. health systems say they will not administer Aduhelm, the controversial new drug for treating Alzheimer disea"
  [3]=>
  string(252) "THURSDAY, July 15, 2021 -- Two major U.S. health systems say they will not administer Aduhelm, the controversial new drug for treating Alzheimer disease.&#nlThe decisions by the Cleveland Clinic and Mount Sinai Health System in New York City are the..."
  ["description"]=>
  string(252) "THURSDAY, July 15, 2021 -- Two major U.S. health systems say they will not administer Aduhelm, the controversial new drug for treating Alzheimer disease.&#nlThe decisions by the Cleveland Clinic and Mount Sinai Health System in New York City are the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(209) "https://www.drugs.com/news/two-major-health-systems-not-administer-controversial-aduhelm-99053.html?utm_source=ddc&utm_medium=rss&utm_campaign=Two+Major+Health+Systems+Will+Not+Administer+Controversial+Aduhelm"
  ["blog_url"]=>
  string(209) "https://www.drugs.com/news/two-major-health-systems-not-administer-controversial-aduhelm-99053.html?utm_source=ddc&utm_medium=rss&utm_campaign=Two+Major+Health+Systems+Will+Not+Administer+Controversial+Aduhelm"
  [15]=>
  string(19) "2021-07-16 05:36:07"
  ["add_date"]=>
  string(19) "2021-07-16 05:36:07"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:47:22"
  ["create_at"]=>
  string(19) "2021-07-16 10:47:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10444"
  ["article_id"]=>
  string(5) "10444"
  [1]=>
  string(57) "R1 RCM to Release Second Quarter 2021 Results on August 3"
  ["article_title"]=>
  string(57) "R1 RCM to Release Second Quarter 2021 Results on August 3"
  [2]=>
  string(150) "MURRAY, Utah, July  15, 2021  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the pati"
  ["short_description"]=>
  string(150) "MURRAY, Utah, July  15, 2021  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the pati"
  [3]=>
  string(370) "
MURRAY, Utah, July  15, 2021  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2021 before market open on Tuesday, August 3, 2021.
"
  ["description"]=>
  string(370) "
MURRAY, Utah, July  15, 2021  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2021 before market open on Tuesday, August 3, 2021.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(129) "https://www.globenewswire.com/news-release/2021/07/15/2263985/0/en/R1-RCM-to-Release-Second-Quarter-2021-Results-on-August-3.html"
  ["blog_url"]=>
  string(129) "https://www.globenewswire.com/news-release/2021/07/15/2263985/0/en/R1-RCM-to-Release-Second-Quarter-2021-Results-on-August-3.html"
  [15]=>
  string(19) "2021-07-16 05:00:00"
  ["add_date"]=>
  string(19) "2021-07-16 05:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10445"
  ["article_id"]=>
  string(5) "10445"
  [1]=>
  string(103) "Baystate Health Collaborates With Cerner to Advance Digital Health and Accelerate Consumer-Focused Care"
  ["article_title"]=>
  string(103) "Baystate Health Collaborates With Cerner to Advance Digital Health and Accelerate Consumer-Focused Care"
  [2]=>
  string(150) "Expansion represents commitment to transform patient care across Western Massachusetts Expansion represents commitment to transform patient care acros"
  ["short_description"]=>
  string(150) "Expansion represents commitment to transform patient care across Western Massachusetts Expansion represents commitment to transform patient care acros"
  [3]=>
  string(184) "Expansion represents commitment to transform patient care across Western Massachusetts 
Expansion represents commitment to transform patient care across Western Massachusetts
"
  ["description"]=>
  string(184) "Expansion represents commitment to transform patient care across Western Massachusetts 
Expansion represents commitment to transform patient care across Western Massachusetts
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(179) "https://www.globenewswire.com/news-release/2021/07/15/2263954/10862/en/Baystate-Health-Collaborates-With-Cerner-to-Advance-Digital-Health-and-Accelerate-Consumer-Focused-Care.html"
  ["blog_url"]=>
  string(179) "https://www.globenewswire.com/news-release/2021/07/15/2263954/10862/en/Baystate-Health-Collaborates-With-Cerner-to-Advance-Digital-Health-and-Accelerate-Consumer-Focused-Care.html"
  [15]=>
  string(19) "2021-07-16 04:30:00"
  ["add_date"]=>
  string(19) "2021-07-16 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10446"
  ["article_id"]=>
  string(5) "10446"
  [1]=>
  string(112) "Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow"
  ["article_title"]=>
  string(112) "Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow"
  [2]=>
  string(166) "TORONTO, July  15, 2021  (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage m"
  ["short_description"]=>
  string(166) "TORONTO, July  15, 2021  (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage m"
  [3]=>
  string(688) "
TORONTO, July  15, 2021  (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021.
"
  ["description"]=>
  string(688) "
TORONTO, July  15, 2021  (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(179) "https://www.globenewswire.com/news-release/2021/07/15/2263958/33471/en/Profound-Medical-to-Release-Second-Quarter-2021-Financial-Results-on-August-4-Conference-Call-to-Follow.html"
  ["blog_url"]=>
  string(179) "https://www.globenewswire.com/news-release/2021/07/15/2263958/33471/en/Profound-Medical-to-Release-Second-Quarter-2021-Financial-Results-on-August-4-Conference-Call-to-Follow.html"
  [15]=>
  string(19) "2021-07-16 04:30:00"
  ["add_date"]=>
  string(19) "2021-07-16 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(5) "10448"
  ["article_id"]=>
  string(5) "10448"
  [1]=>
  string(83) "Shockwave Medical to Report Second Quarter 2021 Financial Results on August 9, 2021"
  ["article_title"]=>
  string(83) "Shockwave Medical to Report Second Quarter 2021 Financial Results on August 9, 2021"
  [2]=>
  string(150) "SANTA CLARA, Calif., July  15, 2021  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of"
  ["short_description"]=>
  string(150) "SANTA CLARA, Calif., July  15, 2021  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of"
  [3]=>
  string(522) "
SANTA CLARA, Calif., July  15, 2021  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2021 before market open on Monday, August 9, 2021. Company management will host a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.  
"
  ["description"]=>
  string(522) "
SANTA CLARA, Calif., July  15, 2021  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2021 before market open on Monday, August 9, 2021. Company management will host a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.  
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(154) "https://www.globenewswire.com/news-release/2021/07/15/2263918/0/en/Shockwave-Medical-to-Report-Second-Quarter-2021-Financial-Results-on-August-9-2021.html"
  ["blog_url"]=>
  string(154) "https://www.globenewswire.com/news-release/2021/07/15/2263918/0/en/Shockwave-Medical-to-Report-Second-Quarter-2021-Financial-Results-on-August-9-2021.html"
  [15]=>
  string(19) "2021-07-16 04:05:00"
  ["add_date"]=>
  string(19) "2021-07-16 04:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2021-07-16 10:48:10"
  ["create_at"]=>
  string(19) "2021-07-16 10:48:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}